GEORGE ROSS

Summary

Affiliation: Pacific Health Research Institute
Country: USA

Publications

  1. ncbi request reprint Association of olfactory dysfunction with incidental Lewy bodies
    G Webster Ross
    Veterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii, USA
    Mov Disord 21:2062-7. 2006
  2. ncbi request reprint Association of olfactory dysfunction with risk for future Parkinson's disease
    G Webster Ross
    Veterans Affairs Pacific Islands Health Care System, University of Hawaii John A Burns School of Medicine, Honolulu, HI 96819, USA
    Ann Neurol 63:167-73. 2008

Detail Information

Publications2

  1. ncbi request reprint Association of olfactory dysfunction with incidental Lewy bodies
    G Webster Ross
    Veterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii, USA
    Mov Disord 21:2062-7. 2006
    ..0 (P = 0.02). Olfactory dysfunction is associated with ILB. If incidental Lewy bodies represent presymptomatic stage of PD, olfactory testing may be a useful screening tool to identify those at high risk for developing PD...
  2. ncbi request reprint Association of olfactory dysfunction with risk for future Parkinson's disease
    G Webster Ross
    Veterans Affairs Pacific Islands Health Care System, University of Hawaii John A Burns School of Medicine, Honolulu, HI 96819, USA
    Ann Neurol 63:167-73. 2008
    ..This study examines the association of olfactory dysfunction with future development of PD in Honolulu-Asia Aging Study cohort members..

Research Grants16

  1. Risk Factors for Pathologic Markers of Parkinson Disease
    GEORGE WEBSTER ROSS; Fiscal Year: 2010
    ..This will also provide opportunity to examine the influence of a wider age range, as well as additional occupational, dietary, medical, constitutional, and environmental exposures on SN neuron density and striatal dopamine levels. ..
  2. RISK FACTORS--PATHOLOGIC MARKERS FOR PARKINSON'S DISEASE
    GEORGE ROSS; Fiscal Year: 2000
    ..Funding for this proposed project will be used for the additional neuropathologic measurements, and for the substantial analyses and presentation activities that will be conducted to utilize the available information. ..
  3. Risk Factors for Pathologic Markers of Parkinson Disease
    GEORGE ROSS; Fiscal Year: 2007
    ..This will also provide opportunity to examine the influence of a wider age range, as well as additional occupational, dietary, medical, constitutional, and environmental exposures on SN neuron density and striatal dopamine levels. ..
  4. Parkinson's Disease Neuroprotection Trial: Hawaii Center
    GEORGE ROSS; Fiscal Year: 2007
    ..The Honolulu Center has the ability to recruit and retain the required number of participants and estimates that 45% will be women and 70% or more will be non-White (mostly Asian/Pacific Islander). ..
  5. Risk Factors for Pathologic Markers of Parkinson Disease
    GEORGE ROSS; Fiscal Year: 2006
    ..This will also provide opportunity to examine the influence of a wider age range, as well as additional occupational, dietary, medical, constitutional, and environmental exposures on SN neuron density and striatal dopamine levels. ..
  6. Risk Factors for Pathologic Markers of Parkinson Disease
    GEORGE ROSS; Fiscal Year: 2005
    ..This will also provide opportunity to examine the influence of a wider age range, as well as additional occupational, dietary, medical, constitutional, and environmental exposures on SN neuron density and striatal dopamine levels. ..
  7. Parkinson's Disease Neuroprotection Trial: Hawaii Center
    GEORGE ROSS; Fiscal Year: 2004
    ..The Honolulu Center has the ability to recruit and retain the required number of participants and estimates that 45% will be women and 70% or more will be non-White (mostly Asian/Pacific Islander). ..
  8. Risk Factors for Pathologic Markers of Parkinson Disease
    GEORGE ROSS; Fiscal Year: 2004
    ..This will also provide opportunity to examine the influence of a wider age range, as well as additional occupational, dietary, medical, constitutional, and environmental exposures on SN neuron density and striatal dopamine levels. ..
  9. RISK FACTORS--PATHOLOGIC MARKERS FOR PARKINSON'S DISEASE
    GEORGE ROSS; Fiscal Year: 2003
    ..Funding for this proposed project will be used for the additional neuropathologic measurements, and for the substantial analyses and presentation activities that will be conducted to utilize the available information. ..
  10. Parkinson's Disease Neuroprotection Trial: Hawaii Center
    GEORGE ROSS; Fiscal Year: 2002
    ..The Honolulu Center has the ability to recruit and retain the required number of participants and estimates that 45% will be women and 70% or more will be non-White (mostly Asian/Pacific Islander). ..
  11. RISK FACTORS--PATHOLOGIC MARKERS FOR PARKINSON'S DISEASE
    GEORGE ROSS; Fiscal Year: 2002
    ..Funding for this proposed project will be used for the additional neuropathologic measurements, and for the substantial analyses and presentation activities that will be conducted to utilize the available information. ..
  12. RISK FACTORS--PATHOLOGIC MARKERS FOR PARKINSON'S DISEASE
    GEORGE ROSS; Fiscal Year: 2001
    ..Funding for this proposed project will be used for the additional neuropathologic measurements, and for the substantial analyses and presentation activities that will be conducted to utilize the available information. ..
  13. RISK FACTORS--PATHOLOGIC MARKERS FOR PARKINSON'S DISEASE
    GEORGE ROSS; Fiscal Year: 2001
    ..Funding for this proposed project will be used for the additional neuropathologic measurements, and for the substantial analyses and presentation activities that will be conducted to utilize the available information. ..
  14. RISK FACTORS--PATHOLOGIC MARKERS FOR PARKINSON'S DISEASE
    GEORGE ROSS; Fiscal Year: 2001
    ..Funding for this proposed project will be used for the additional neuropathologic measurements, and for the substantial analyses and presentation activities that will be conducted to utilize the available information. ..